about
The potential role of thioredoxin 1 and CD30 systems as multiple pathway targets and biomarkers in tumor therapy.Gender-specific cytokine pathways, targets, and biomarkers for the switch from health to adenoma and colorectal cancer.A gender-related action of IFNbeta-therapy was found in multiple sclerosis.Ageing gender-specific "Biomarkers of Homeostasis", to protect ourselves against the diseases of the old age.Passage from normal mucosa to adenoma and colon cancer: alteration of normal sCD30 mechanisms regulating TH1/TH2 cell functions.The Role of Gender-specific Cytokine Pathways as Drug Targets and Gender- specific Biomarkers in Personalized Cancer Therapy.Relationships between the activity of MMP1/TIMP1 enzymes and the TH1/TH2 cytokine network.Immunological study of IFNbeta-1a-treated and untreated multiple sclerosis patients: clarifying IFNbeta mechanisms and establishing specific dendritic cell immunotherapy.Soluble CD30: a biomarker for evaluating the clinical risk versus benefit of IFNbeta1A treatment in multiple sclerosis patients.Colon cancer and gene alterations: their immunological implications and suggestions for prognostic indices and improvements in biotherapy.Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progressionProgression mechanisms in colon cancer: soluble interleukin-2 (IL-2) receptor, IL-2 plus anti-CD3 proliferative response and tumour stage correlationsCytokine contribution to the repair processes and homeostasis recovery following anoxic insult: a possible IFN-gamma-regulating role in IL-1beta neurotoxic action in physiological or damaged CNSCell cycle control in cellular homeostasis during the immune response: interactions between TH1, TH2 cytokines, and Bcl2 and p53 moleculesDisease stage prognostic indices in the early clinical screening of colorectal cancer patientsThe sCEA molecule suppressive role in NK and TH1 cell functions in colorectal cancerIL-10 and sIL-2R serum levels as possible peripheral blood prognostic markers in the passage from adenoma to colorectal cancerThe role of the soluble CD30 serum level in colorectal cancer: a possible marker for a patient subset which could benefit from IL-2 biotherapyImmunological implications of alterations in the c-Ki-ras and p53 genes in the stepwise progression of colorectal cancer: indications for the improvement of prognosis, biotherapy treatment and tumor biology understandingPrognostic significance of immunological evaluation in colorectal cancerNecessity of biotherapeutic treatments inducing TH1 cell functions in colorectal cancerImmunological directives for biotherapy improvement in the treatment of colorectal cancerThe significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 to TH2 and backSimultaneous measurement of soluble carcinoembryonic antigen and the tissue inhibitor of metalloproteinase TIMP1 serum levels for use as markers of pre-invasive to invasive colorectal cancerPeripheral blood immunological parameters for use as markers of pre-invasive to invasive colorectal cancerCD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 responseThe study of a patient's immune system may prove to be a useful noninvasive tool for stage classification in colon cancerAre immunological mechanisms involved in colon cancer and are they possible markers for biotherapy improvement?IFNbeta-1a treatment and reestablishment of Th1 regulation in MS patients: dose effectsCD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. T
P50
Q35222365-BF1151AC-55C5-4F16-BB69-3FD3A03C3165Q35659961-59760AE0-842F-42F6-978A-DF74334899E3Q36594388-2A28E1C0-1191-4C85-B665-215DB59D0FEEQ37581323-70D23D45-18EC-445A-BBEC-213CF455E38FQ47612404-DCC31409-BC19-4990-AD7D-AB643E611154Q51651751-060AD276-C79B-48F0-9046-27DD635E71EFQ52077578-D1308ECA-B750-40F4-8FFA-F14E1E2F6C3DQ52563077-A6EE496F-8DBD-4705-9B24-E965CD5E327AQ52599699-B0E86E2D-08FE-4A2F-BDD8-DF830D8E351CQ53340003-9A7FFF96-30E9-47AC-A4BB-19E509A2664BQ71067755-DBBB0297-326D-41D4-84A2-6EECAE6334E1Q72670663-8E91F576-FC1B-4950-9174-5F5E3515EAA5Q73204913-53294EB0-E454-4AAA-ABB1-219470A8608CQ73695885-944A1225-D88B-4588-B9D9-9C194502671DQ73886731-F00AA5A1-BA3E-49A9-9609-35E4C4178D87Q73889975-A0176EC3-F26D-437D-B8BF-4694EFF9294EQ73889980-066BD275-E712-4D0A-8205-44685896D602Q73890007-74673DB6-BB52-46C4-9E91-CA1B7981B8F7Q73890072-29552303-4DE1-4EB3-B9C9-708B2619FB9BQ73890091-02DE4038-B70A-4420-948D-FB8BAB22A1EBQ73890097-82450E6C-279A-415A-8C3A-F95E9F992F40Q73890189-3E320E68-2659-4BF8-A3CA-D6C6A7A6EFD5Q74079410-4EBEB86B-9950-40A9-B919-F93D446DDE7EQ74351295-9E7ED8AB-2B46-449C-9F84-0EFE103803C8Q77823994-FE241309-4C82-444B-B9F9-C2D9DDC9026DQ79150247-1F6E2DEC-B472-4BDE-A2DC-9F71C645D601Q79359133-F56EA7A7-B1F4-4C55-B72E-DFD8023FBD5AQ79359135-74475BB9-7673-4123-831A-5EC1D44968C0Q81186274-8D00577B-507B-402F-A393-86D19BA3DB10Q81913074-E64EBF89-A8B6-49E6-9C05-90B9E257914C
P50
description
researcher
@en
name
P Pellegrini
@en
P Pellegrini
@nl
type
label
P Pellegrini
@en
P Pellegrini
@nl
prefLabel
P Pellegrini
@en
P Pellegrini
@nl
P106
P31
P496
0000-0002-2758-9391